CA2116334A1 - Oxytocin antagonist - Google Patents

Oxytocin antagonist

Info

Publication number
CA2116334A1
CA2116334A1 CA 2116334 CA2116334A CA2116334A1 CA 2116334 A1 CA2116334 A1 CA 2116334A1 CA 2116334 CA2116334 CA 2116334 CA 2116334 A CA2116334 A CA 2116334A CA 2116334 A1 CA2116334 A1 CA 2116334A1
Authority
CA
Canada
Prior art keywords
optionally
substituted
alkyl
alkoxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2116334
Other languages
English (en)
French (fr)
Inventor
Hidenori Ogawa
Hisashi Miyamoto
Kazumi Kondo
Hiroshi Yamashita
Kenji Nakaya
Michinori Tanaka
Kazuyoshi Kitano
Keizo Kan
Michiaki Tominaga
Yoichi Yabuuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2116334A1 publication Critical patent/CA2116334A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA 2116334 1992-07-02 1993-06-22 Oxytocin antagonist Abandoned CA2116334A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP17556392 1992-07-02
JP175563/1992 1992-07-02
JP17556692 1992-07-02
JP175566/1992 1992-07-02

Publications (1)

Publication Number Publication Date
CA2116334A1 true CA2116334A1 (en) 1994-01-20

Family

ID=26496804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2116334 Abandoned CA2116334A1 (en) 1992-07-02 1993-06-22 Oxytocin antagonist

Country Status (8)

Country Link
EP (1) EP0602209A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1091288A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU657424B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2116334A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID15999A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9304015A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW249201B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1994001113A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356904A (en) * 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
GB9307527D0 (en) * 1993-04-13 1993-06-02 Fujisawa Pharmaceutical Co New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
WO1995002405A1 (en) * 1993-07-16 1995-01-26 Merck & Co., Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
EP0805681A4 (en) * 1995-01-24 1998-05-06 Merck & Co Inc TOCOLYTIC ANTAGONISTS OF OXYTOCIN RECEPTORS
TW359669B (en) * 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
US5726172A (en) * 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
AR011913A1 (es) 1997-03-06 2000-09-13 Yamano Masaki Derivados de 4,4-difluoro-2,3,4,5-tetrahidro-1h-1-benzoazepina y composiciones farmaceuticas de los mismos.
US7109193B2 (en) 2001-04-12 2006-09-19 Wyeth Tricyclic diazepines tocolytic oxytocin receptor antagonists
US7022699B2 (en) 2001-04-12 2006-04-04 Wyeth Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators
US6977254B2 (en) 2001-04-12 2005-12-20 Wyeth Hydroxy cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US7202239B2 (en) 2001-04-12 2007-04-10 Wyeth Cyclohexylphenyl carboxamides tocolytic oxytocin receptor antagonists
US7064120B2 (en) 2001-04-12 2006-06-20 Wyeth Tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
US7326700B2 (en) 2001-04-12 2008-02-05 Wyeth Cyclohexenyl phenyl carboxamides tocolytic oxytocin receptor antagonists
US6900200B2 (en) 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
US20050228016A1 (en) * 2002-06-13 2005-10-13 Enrique Michelotti Tetrahydroquinolines for modulating the expression of exogenous genes via an ecdysone receptor complex
NZ537858A (en) 2002-07-15 2008-04-30 Myriad Genetics Inc Compounds, compositions, and methods employing same
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006508077A (ja) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのpgd2レセプタアンタゴニスト
EP1554260A1 (en) * 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivatives as h3 receptor ligands
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
TWI322689B (en) 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
JP2008543726A (ja) 2005-02-24 2008-12-04 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症性疾患の処置のためのpgd2受容体アンタゴニスト
US7671058B2 (en) 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
CN101686983A (zh) 2007-05-10 2010-03-31 Amr科技公司 芳基和杂芳基取代的四氢苯并-1,4-二氮杂䓬及其阻断去甲肾上腺素、多巴胺和5-羟色胺重摄取的用途
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
CN102030709B (zh) * 2009-09-25 2013-10-16 江苏豪森医药集团有限公司 用作加压素受体拮抗剂的苯并氮杂卓类化合物
US9102669B2 (en) 2011-12-06 2015-08-11 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
WO2013085954A1 (en) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Substituted piperidinyl-carboxamide derivatives useful as scd 1 inhibitors
WO2017156164A1 (en) 2016-03-09 2017-09-14 Board Of Regents, The University Of Texas System 20-hete receptor (gpr75) antagonists and methods of use
WO2019003433A1 (ja) 2017-06-30 2019-01-03 大塚製薬株式会社 ベンゾアゼピン誘導体
KR20210040368A (ko) * 2018-06-29 2021-04-13 킨네이트 바이오파마 인크. 사이클린 의존성 키나제의 억제제
US20240101568A1 (en) * 2020-11-26 2024-03-28 Shanghai Jemincare Pharmaceutical Co., Ltd Novel benzazepine spiro derivative
CN112851583B (zh) * 2021-01-19 2023-09-08 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0382185T3 (da) * 1989-02-10 1994-07-04 Otsuka Pharma Co Ltd Carbostyrilderivater
CA2026856A1 (en) * 1989-10-05 1991-04-06 Mark G. Bock 3-substituted-1,4-benzodiazepines useful as oxytocin
DE69026708T2 (de) * 1989-10-20 1997-04-03 Otsuka Pharma Co Ltd Benzoheterozyklische verbindungen
TW199153B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-08-07 1993-02-01 Dtsuka Seiyaku Kk

Also Published As

Publication number Publication date
AU4356993A (en) 1994-01-31
ID15999A (id) 1997-08-21
TW249201B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1995-06-11
MX9304015A (es) 1994-02-28
EP0602209A1 (en) 1994-06-22
CN1091288A (zh) 1994-08-31
AU657424B2 (en) 1995-03-09
WO1994001113A1 (en) 1994-01-20

Similar Documents

Publication Publication Date Title
CA2116334A1 (en) Oxytocin antagonist
TWI327570B (en) Fused azole-pyrimidine derivatives
AU2007269070B2 (en) Bicyclic heteroaryl inhibitors of PDE4
JP7203752B2 (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
WO2005080399A1 (ja) 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
TWI771420B (zh) 作為登革熱病毒複製抑制劑之經取代之吲哚啉衍生物(一)
CZ161993A3 (en) Peptides capable of inhibiting activity of hiv protease, their preparation and therapeutic use
AU2009799A (en) 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor
AU2016202949A1 (en) Novel nicotinamide derivative or salt thereof
WO2001021169A1 (fr) Antagonistes de l'hormone de concentration de la melanine
US20040068109A1 (en) Diazepan derivatives or salts thereof
CN102532162A (zh) 2,3-二氢-6-硝基咪唑并[2,1-b]噁唑化合物
WO2001047883A1 (en) Fused-ring compounds and use thereof as drugs
JPH09505036A (ja) 喘息治療用のニューロキニン2受容体拮抗薬としての新規な4−ピペリジニル置換ラクタム
JP2004517072A (ja) Cns障害の治療において有用な化合物
JP2019510034A (ja) デングウイルス複製阻害剤としての置換インドリン誘導体
EP2155728A2 (de) Heterocyclische indazolderivate
EP2003131A1 (en) Aminopyrrolidine compound
CA2770767A1 (en) Bicyclic heteroaryl inhibitors of pde4
EP0694536A1 (fr) Dérivés de 1-benzyl-1,3-dihydro-2H-benzimidazol-2-one, leur préparation, et compositions pharmaceutiques les contenant
WO2007015157A2 (en) Mc4r-ag0nists for the treatment of urinary tract dysfunction
WO2006057270A1 (ja) 含窒素3環化合物
EP3190111B1 (en) Pyrazolo[3,4-c]pyridine derivatives
WO2019185046A1 (zh) 四元内酰胺类化合物及其药学用途
TW200819455A (en) Pyrrolizine, indolizine and quinolizine derivatives, their preparation and their therapeutic application

Legal Events

Date Code Title Description
FZDE Dead